Outcomes of COVID-19 and Vaccination in Patients With Moderate to Severe Atopic Dermatitis Treated With Tralokinumab

This case series describes the outcomes of COVID-19 and SARS-CoV-2 vaccination in patients with atopic dermatitis who have been treated with tralokinumab.

Detalles Bibliográficos
Autores principales: Blauvelt, Andrew, Pink, Andrew, Worm, Margitta, Langley, Richard G. B., Elewski, Boni E., Gjerum, Le, Guttman-Yassky, Emma
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2022
Materias:
Research Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9558055/
https://www.ncbi.nlm.nih.gov/pubmed/36223087
http://dx.doi.org/10.1001/jamadermatol.2022.3488

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9558055/
https://www.ncbi.nlm.nih.gov/pubmed/36223087
http://dx.doi.org/10.1001/jamadermatol.2022.3488

Ejemplares similares